Kurt A. Schalper

24.5k total citations · 9 hit papers
166 papers, 11.2k citations indexed

About

Kurt A. Schalper is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Kurt A. Schalper has authored 166 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 60 papers in Immunology and 45 papers in Molecular Biology. Recurrent topics in Kurt A. Schalper's work include Cancer Immunotherapy and Biomarkers (99 papers), Immunotherapy and Immune Responses (41 papers) and Immune Cell Function and Interaction (18 papers). Kurt A. Schalper is often cited by papers focused on Cancer Immunotherapy and Biomarkers (99 papers), Immunotherapy and Immune Responses (41 papers) and Immune Cell Function and Interaction (18 papers). Kurt A. Schalper collaborates with scholars based in United States, Chile and Spain. Kurt A. Schalper's co-authors include David L. Rimm, Vamsidhar Velcheti, Roy S. Herbst, Anant Madabhushi, Daniel Carvajal‐Hausdorf, Miguel F. Sanmamed, Scott Gettinger, Kaustav Bera, Lieping Chen and Juan C. Sáez and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Kurt A. Schalper

163 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology

2019 935 citations Kurt A. Schalper, David L. Rimm et al. profile →
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

2015 679 citations Joseph McLaughlin, Kurt A. Schalper et al. profile →
Programmed death ligand-1 expression in non-small cell lung cancer

2013 652 citations Vamsidhar Velcheti, Kurt A. Schalper et al. profile →
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

2019 470 citations Deborah B. Doroshow, Miguel F. Sanmamed et al. Clinical Cancer Research profile →
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

2019 449 citations Kurt A. Schalper, María E. Rodríguez-Ruiz et al. profile →
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

2019 405 citations David L. Rimm, Kurt A. Schalper et al. profile →
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

2014 367 citations Kurt A. Schalper, Vamsidhar Velcheti et al. Clinical Cancer Research profile →
The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion

2023 124 citations Anna-Maria Globig, Steven Zhao et al. Nature profile →
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach

2025 21 citations Miguel F. Sanmamed, Lieping Chen et al. profile →

Peers

Countries citing papers authored by Kurt A. Schalper

Since Specialization

Citations

This map shows the geographic impact of Kurt A. Schalper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt A. Schalper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt A. Schalper more than expected).

Fields of papers citing papers by Kurt A. Schalper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt A. Schalper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt A. Schalper. The network helps show where Kurt A. Schalper may publish in the future.

Co-authorship network of co-authors of Kurt A. Schalper

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt A. Schalper. A scholar is included among the top collaborators of Kurt A. Schalper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt A. Schalper. Kurt A. Schalper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities 2024 ·Journal for ImmunoTherapy of Cancer ·Álvaro López‐Janeiro, (unknown), (unknown), Carlos Ortíz-de-Solórzano, María D. Lozano, Álvaro Teijeira, Kurt A. Schalper, Ignacio Melero, Carlos E. de Andrea	5
2	Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer 2023 ·Cancer Research Communications ·Michael Cecchini, Janie Y. Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, (unknown), Lesley Devine, Stacey Stein, Jeremy Kortmansky, Kimberly L. Johung, Ranjit S. Bindra, Patricia LoRusso, Kurt A. Schalper	4
3	NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors 2023 ·Cancer Research Communications ·Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A. Boerner, Diane E. Durecki, Joseph P. Eder, Kurt A. Schalper, Alice P. Chen, Patricia LoRusso	2
4	Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy 2023 ·Cell Reports ·Sudipta Biswas, Kai Kang, Kwok Peng Ng, Tomas Radivoyevitch, Kurt A. Schalper, (unknown), Daniel J. Lindner, Anish Thomas, David MacPherson, Brian Gastman, David S. Schrump, Kwok‐Kin Wong, Vamsidhar Velcheti, Yogen Saunthararajah	2
5	The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion breakdown → 2023 ·Nature ·Anna-Maria Globig, Steven Zhao, (unknown), Vivien I. Maltez, (unknown), (unknown), Maximilian Heeg, Filipe Araujo Hoffmann, Omkar Chaudhary, Jiawei Wang, (unknown), Dan Chen, Carolyn O’Connor, Samuel L. Pfaff, Ronald N. Germain, Kurt A. Schalper, Brinda Emu, Susan M. Kaech	124
6	Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling 2022 ·Journal of Thoracic Oncology ·Myrto Moutafi, Sandra Martínez-Morilla, Prajan Divakar, (unknown), Niki Gavrielatou, Thazin Nwe Aung, Vesal Yaghoobi, Aileen I. Fernandez, Jon Zugazagoitia, Roy S. Herbst, Kurt A. Schalper, David L. Rimm	23
7	Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer 2021 ·Clinical Cancer Research ·Ila Datar, Sacha C. Hauc, Shruti Desai, Nicole Gianino, Brian S. Henick, Yuting Liu, Kostas Syrigos, David L. Rimm, Paula Kavathas, Soldano Ferrone, Kurt A. Schalper	26
8	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry 2021 ·Clinical Cancer Research ·Sandra Martínez-Morilla, Franz Villarroel‐Espíndola, Pok Fai Wong, Maria Toki, Thazin Nwe Aung, Vasiliki Pelekanou, (unknown), Kurt A. Schalper, Harriet M. Kluger, David L. Rimm	42
9	Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling 2020 ·Clinical Cancer Research ·Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit Fuhrman, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm	83
10	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy 2019 ·Clinical Cancer Research ·Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S. Henick, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm	225
11	Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry 2019 ·Clinical Cancer Research ·Daniel Carvajal‐Hausdorf, (unknown), Kelly Stanton, Franz Villarroel‐Espíndola, Amanda Esch, Ruth R. Montgomery, Amanda Psyrri, Konstantine T. Kalogeras, Vassiliki Kotoula, (unknown), Kurt A. Schalper, Yuval Kluger, David L. Rimm	40
12	Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes breakdown → 2019 ·Clinical Cancer Research ·Deborah B. Doroshow, Miguel F. Sanmamed, Katherine Hastings, Katerina Politi, David L. Rimm, Lieping Chen, Ignacio Melero, Kurt A. Schalper, Roy S. Herbst	470
13	Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer 2018 ·Clinical Cancer Research ·Germán Corredor, Xiangxue Wang, Yu Zhou, Cheng Lu, Pingfu Fu, Konstantinos Syrigos, David L. Rimm, Michael Yang, Eduardo Romero, Kurt A. Schalper, Vamsidhar Velcheti, Anant Madabhushi	162
14	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes 2017 ·Clinical Cancer Research ·Mehmet Altan, Vasiliki Pelekanou, Kurt A. Schalper, Maria Toki, Patricia Gaule, Konstantinos Syrigos, Roy S. Herbst, David L. Rimm	108
15	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer 2017 ·Clinical Cancer Research ·Franz Villarroel‐Espíndola, Xiaoqing Yu, Ila Datar, Nikita Mani, Miguel F. Sanmamed, Vamsidhar Velcheti, Konstantinos Syrigos, Maria Toki, Hongyu Zhao, Lieping Chen, Roy S. Herbst, Kurt A. Schalper	162
16	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming 2016 ·Cancer Research ·María E. Rodríguez-Ruiz, Inmaculada Rodríguez, Saray Garasa, Benigno Barbés, José Luis Solórzano, José Luis Perez‐Gracia, Sara Labiano, Miguel F. Sanmamed, Arantza Azpilikueta, Elixabet Bolaños, Alfonso R. Sánchez-Paulete, (unknown), Ana Rouzaut, Kurt A. Schalper, Maria Jure–Kunkel, Ignacio Melero	198
17	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer 2016 ·Clinical Cancer Research ·Kurt A. Schalper, Daniel Carvajal‐Hausdorf, Joseph McLaughlin, Mehmet Altan, Vamsidhar Velcheti, Patricia Gaule, Miguel F. Sanmamed, Lieping Chen, Roy S. Herbst, David L. Rimm	160
18	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice 2015 ·Cancer Research ·Miguel F. Sanmamed, Inmaculada Rodríguez, Kurt A. Schalper, Carmen Oñate, Arantza Azpilikueta, María E. Rodríguez-Ruiz, Aizea Morales‐Kastresana, Sara Labiano, José Luis Perez‐Gracia, Salvador Martín‐Algarra, Carlos Alfaro, Guillermo Mazzolini, Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure–Kunkel, Ignacio Melero	129
19	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer 2014 ·Cancer Immunology Research ·Hallie Wimberly, Jason R. Brown, Kurt A. Schalper, Herbert Haack, Matthew R. Silver, Christian P. Nixon, Veerle Bossuyt, Lajos Pusztai, Donald R. Lannin, David L. Rimm	312
20	Modulation of gap junction channels and hemichannels by growth factors 2012 ·Molecular BioSystems ·Kurt A. Schalper, Manuel A. Riquelme, María C. Brañes, Agustı́n D. Martı́nez, José Luis Vega, Viviana M. Berthoud, Michael V. L. Bennett, Juan C. Sáez	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact